The ß-ARs play an important role in CV health and disease and are mainstay targets of ß blockers in the treatment of hypertension, congestive HF, and coronary disease. Both genetic association and ...
Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results